Literature DB >> 18402715

Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature.

G Dolan1, L A Smith, S Collins, J M Plumb.   

Abstract

OBJECTIVES: To investigate the relationship between time spent in the recommended target International Normalised Ratio (INR) range and the setting and intensity of anti coagulant monitoring, in both treatment-experienced and treatment-naive atrial fibrillation (AF) patients receiving oral anticoagulation (OAC) therapy for the prevention of ischaemic stroke. RESEARCH DESIGN AND METHODS: Systematic review of published studies on participants with atrial fibrillation on anticoagulation therapy. We compared frequent monitoring (well-controlled, according to a strict protocol) versus infrequent monitoring (frequency representative of routine clinical practice), specialised care versus usual care, and naive versus prior anticoagulant use. Meta-analysis was performed using a random effects model.
RESULTS: 36 studies were included, 22 (primary data) of AF patients managed in line with the consensus guidelines target INR range of 2.0-3.0, and 14 studies (secondary data) of mixed patient groups, including AF, with an INR target of 2.0-3.5. Both data sets were combined for sensitivity analysis. Pooled mean time in INR range was 59.1% (95% CI: 55.5, 62.8%) and 64.3% (95% CI: 60.5, 68.0%) for infrequent monitoring and frequent monitoring, respectively. Significantly more time was spent in range in specialist care settings compared to usual care: +11.3% (95% CI: 0.1-21.7%). Naive OAC users spent less time in range 56.5% (95% CI: 45.5-67.5%) than existing users 61.2% (95% CI: 57.2-65.2%). All of these differences were found to be significant in the sensitivity analyses.
CONCLUSIONS: INR control is variable and dependent on monitoring intensity and duration of anticoagulant therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18402715     DOI: 10.1185/030079908x297349

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

1.  Dabigatran in atrial fibrillation: New kid on the block.

Authors:  Timothy S Leung; Miriam Fradette; Ann Thompson; Sheri L Koshman
Journal:  Can Pharm J (Ott)       Date:  2012-03

2.  Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

Authors:  Stephen E Kimmel; Benjamin French; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Yves D Rosenberg; Nancy L Geller; Scott E Kasner; Charles S Eby; Jungnam Joo; Michael D Caldwell; Samuel Z Goldhaber; Robert G Hart; Denise Cifelli; Rosemary Madigan; Colleen M Brensinger; Suzanne Goldberg; Robert M Califf; Jonas H Ellenberg
Journal:  Am Heart J       Date:  2013-07-12       Impact factor: 4.749

3.  The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes.

Authors:  Sherrie L Aspinall; Xinhua Zhao; Steven M Handler; Roslyn A Stone; Janine C Kosmoski; Elizabeth A Libby; Susan Dove Francis; David A Goodman; Rebecca D Roman; Heather L Bieber; Jennifer M Voisine; Sean M Jeffery; Charley A Hepfinger; Diane G Hagen; Micki M Martin; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2010-07-19       Impact factor: 5.562

4.  Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.

Authors:  Martin Krejczy; Job Harenberg; Svetlana Marx; Konrad Obermann; Lutz Frölich; Martin Wehling
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

5.  Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg
Journal:  Trials       Date:  2010-11-17       Impact factor: 2.279

6.  A pre- post-evaluation of implementing an inpatient warfarin monitoring and education program.

Authors:  Edward P Armstrong; Lucy Chemodurow; Shanna Christensen; E Suzanne Johnson
Journal:  Pharm Pract (Granada)       Date:  2011-06-17

7.  Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study.

Authors:  Teferi Gedif Fenta; Tamrat Assefa; Bekele Alemayehu
Journal:  BMC Health Serv Res       Date:  2017-06-06       Impact factor: 2.655

Review 8.  What methods are being used to create an evidence base on the use of laboratory tests to monitor long-term conditions in primary care? A scoping review.

Authors:  Martha M C Elwenspoek; Lauren J Scott; Katharine Alsop; Rita Patel; Jessica C Watson; Ed Mann; Penny Whiting
Journal:  Fam Pract       Date:  2020-11-28       Impact factor: 2.267

Review 9.  Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.

Authors:  Rebecca Ryan; Nancy Santesso; Dianne Lowe; Sophie Hill; Jeremy Grimshaw; Megan Prictor; Caroline Kaufman; Genevieve Cowie; Michael Taylor
Journal:  Cochrane Database Syst Rev       Date:  2014-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.